Angela A. Armstrong

Array ( [id] => 16492397 [patent_doc_number] => 10858422 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-08 [patent_title] => Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody [patent_app_type] => utility [patent_app_number] => 16/428631 [patent_app_country] => US [patent_app_date] => 2019-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 152 [patent_no_of_words] => 57568 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16428631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19256892 [patent_doc_number] => 12016921 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => Methods for treatment of psoriasis with an anti-Apo B100 antibody [patent_app_type] => utility [patent_app_number] => 17/058537 [patent_app_country] => US [patent_app_date] => 2019-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 20897 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17058537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16962927 [patent_doc_number] => 20210214426 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF RHEUMATOID ARTHRITIS AND ACCELERATED ATHEROSCLEROSIS [patent_app_type] => utility [patent_app_number] => 17/058508 [patent_app_country] => US [patent_app_date] => 2019-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16279 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17058508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17821524 [patent_doc_number] => 11426448 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => Methods for treatment of erectile dysfunction with sonic hedgehog compounds [patent_app_type] => utility [patent_app_number] => 16/410789 [patent_app_country] => US [patent_app_date] => 2019-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 66 [patent_no_of_words] => 25006 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16410789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18947067 [patent_doc_number] => 11890340 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-06 [patent_title] => Use of epithelial membrane protein 2 [EMP2] targeting agents in treating lung disorders [patent_app_type] => utility [patent_app_number] => 17/051678 [patent_app_country] => US [patent_app_date] => 2019-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 58 [patent_no_of_words] => 15822 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 258 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17051678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18187566 [patent_doc_number] => 11578135 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-14 [patent_title] => Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/394849 [patent_app_country] => US [patent_app_date] => 2019-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 12180 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16394849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657449 [patent_doc_number] => 20210054085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRB ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/050261 [patent_app_country] => US [patent_app_date] => 2019-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39762 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -148 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17050261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18187566 [patent_doc_number] => 11578135 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-14 [patent_title] => Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/394849 [patent_app_country] => US [patent_app_date] => 2019-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 12180 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16394849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16999503 [patent_doc_number] => 11078295 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases [patent_app_type] => utility [patent_app_number] => 16/392451 [patent_app_country] => US [patent_app_date] => 2019-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 30154 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16392451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16822638 [patent_doc_number] => 20210137931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => SELECTING PATIENTS FOR THERAPY WITH ADENOSINE SIGNALING INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/049739 [patent_app_country] => US [patent_app_date] => 2019-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17049739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18051619 [patent_doc_number] => 11524990 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-13 [patent_title] => Methods for treating vascular eye disorders with ActRII antagonists [patent_app_type] => utility [patent_app_number] => 16/380196 [patent_app_country] => US [patent_app_date] => 2019-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 24 [patent_no_of_words] => 75298 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16380196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18413174 [patent_doc_number] => 11667707 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => SPNS2 neutralizing antibody [patent_app_type] => utility [patent_app_number] => 17/045398 [patent_app_country] => US [patent_app_date] => 2019-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 23 [patent_no_of_words] => 54006 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17045398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206409 [patent_doc_number] => 20190365891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => ANTI-PRO/LATENT-MYOSTATIN ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/374854 [patent_app_country] => US [patent_app_date] => 2019-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31904 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16374854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15175433 [patent_doc_number] => 20190358308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => THROMBOXANE RECEPTOR-BASED VACCINE FOR MANAGING THROMBOGENESIS [patent_app_type] => utility [patent_app_number] => 16/374390 [patent_app_country] => US [patent_app_date] => 2019-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16374390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14926379 [patent_doc_number] => 20190298827 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => Methods of Treating Multiple Myeloma [patent_app_type] => utility [patent_app_number] => 16/374031 [patent_app_country] => US [patent_app_date] => 2019-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16068 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16374031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17406064 [patent_doc_number] => 11246925 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Human antibodies to PCSK9 for use in methods of treating particular groups of subjects [patent_app_type] => utility [patent_app_number] => 16/365317 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 65645 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16365317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16549755 [patent_doc_number] => 10882904 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-05 [patent_title] => Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies [patent_app_type] => utility [patent_app_number] => 16/360142 [patent_app_country] => US [patent_app_date] => 2019-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 114 [patent_no_of_words] => 68894 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16360142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555727 [patent_doc_number] => 20210000875 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => IL-13 RECEPTOR ALPHA 2 (IL13RA2) CHIMERIC ANTIGEN RECEPTOR FOR TUMOR SPECIFIC T CELL IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/979471 [patent_app_country] => US [patent_app_date] => 2019-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19354092 [patent_doc_number] => 12054521 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-06 [patent_title] => FhuD2 fusion proteins for the outer membrane vesicle (OMV) delivery of heterologous polypetides and immunogenic compositions thereof [patent_app_type] => utility [patent_app_number] => 16/978807 [patent_app_country] => US [patent_app_date] => 2019-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 15 [patent_no_of_words] => 12763 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16978807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836253 [patent_doc_number] => 20190276527 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => METHODS FOR ALTERING BODY COMPOSITION [patent_app_type] => utility [patent_app_number] => 16/290287 [patent_app_country] => US [patent_app_date] => 2019-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16290287 [rel_patent_id] =>[rel_patent_doc_number] =>)